ALSO NOTED: Memory refocuses on lead programs; GRL, Sirnaomics extend RNAi deal;and much more...

> Memory Pharmaceuticals is retooling its operations to focus less on drug discovery research a near-term and mid-term efforts. Report

> General Research Laboratory (GRL) and Sirnaomics are advancing their partnership initiated in July 2007 for development of two RNAi therapeutic products. Release

> Japan-based TPG Biotech and JCR Pharmaceuticals jointly announced that they have entered into an investment agreement to fund the late-stage clinical development of two drug candidates for JCR, JR-013 and Growject. Release

> Northwestern University scientist Richard Silverman's work led to the blockbuster Lyrica, which translated into more than $700 million in royalties from Pfizer. And his story--told by the Chicago Tribune--illustrates the crucial role that a technology transfer office can play in moving an experimental therapy into the hands of a biopharma company with deep pockets. Report

> The FDA is taking a look at a fresh set of standards that demand new tests to determine if diabetes drugs elevate heart risks. Report

> A group of some of the most prestigious research groups in the country says that five years of flat budgets for the National Institutes of Health is threatening to deter an entire generation of young researchers. Report

> Connecticut is joining the queue of states suing Eli Lilly over Zyprexa marketing. Report

> Scientists at the Virginia Bioinformatics Institute used a new computer modeling program supported by the NIH to simulate how a lethal pandemic flu outbreak could hit a modern American city. Report

> Since the Democrats took over Congress, drug makers have been scrambling to make nice with their former foes. Report

And Finally... According to a news CDC study, one in four teenage girls has an STD. Release

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.